Marinus Pharma to explore options as rare disease drug fails trial (updated)

Marinus Pharmaceuticals

24/10/2024 13:42

(Adds shares, details on planned steps and background in
paragraphs 2-5)
       Oct 24 (Reuters) - Marinus Pharmaceuticals  MRNS.O  said
on Thursday it is exploring alternatives after the company's
drug for treating seizures related to a rare brain disease
failed to meet the main goal in a late-stage study.
    The company's shares were down 65% to 56 cents in premarket
trading.
    Marinus said it will discontinue development of the drug,
ganaxolone, and take further steps to reduce costs, including
job cuts. It did not disclose the number of jobs that would be
affected.
    In June, an intravenous version of ganaxolone for a type of
seizure known as refractory status epilepticus had also failed
to meet one of the two key goals in a late-stage study.
    Marinus was developing the oral version of the drug for the
treatment of seizures associated with tuberous sclerosis complex
in children and adults.

 (Reporting by Sruthi Narasimha Chari in Bengaluru; Editing by
Abinaya Vijayaraghavan and Shounak Dasgupta)
 ((SruthiNarasimha.Chari@thomsonreuters.com))